The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for FUROSCIX ® (furosemide) On-body Infusor, expanding the indication of this product to include ...

Credit: scPharmaceuticals. Furoscix is a pH-neutral formulation of furosemide designed for SC administration via a wearable, single-use, pre-programmed on-body infusor for outpatient ...

Credit: scPharmaceuticals. Previously, the novel furosemide delivery system was only indicated for congestion due to fluid overload in adult patients with NYHA Class II and Class III CHF. The Furoscix ...

BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

ELK GROVE VILLAGE, Ill., Oct. 21, 2024 /PRNewswire/ -- Orsini announced today that it has been chosen by scPharmaceuticals to distribute FUROSCIX® (furosemide injection) 80 mg/10mL for subcutaneous ...

Shares of scPharmaceuticals (SCPH) have lost 37% of their value over the past three years and are down 11% so far in 2025. Interestingly, Furoscix was approved in October 2022 with share price peaking ...

(RTTNews) - scPharmaceuticals Inc. (SCPH) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX to expand the indication to ...

MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD’s 2026 business outlook highlights ...

BURLINGTON, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced two business updates-approval of the FUROSCIX® (furosemide) ...